Iconovo (ICO) Q2 2024 earnings summary

Executive summary

• Q2 2024 focused on strategic business development, patent expansion, and licensing negotiations, particularly for ICOpre® and new inhaled GLP-1 obesity treatments.

• Patent protection for ICOres® was extended to China, strengthening global IP coverage until 2040.

• The licensing process for ICOpre® is in advanced negotiations, with a deal expected by Q3 2024.

• Iconovo is targeting the rapidly growing GLP-1 market, aiming to license inhaled obesity treatments after preclinical proof-of-concept.

• The company continues to see strong demand for its inhaler platforms from international pharma partners.

Financial highlights

• Net sales for Q2 2024 were SEK 249k, down from SEK 2,621k in Q2 2023; H1 2024 net sales were SEK 1,948k, down from SEK 2,929k year-over-year.

• Operating result for Q2 2024 was SEK -9,660k, an improvement from SEK -13,082k in Q2 2023; H1 2024 operating result was SEK -19,233k vs. SEK -25,966k year-over-year.

• Q2 2024 net loss was SEK -9,607k (Q2 2023: SEK -13,069k); H1 2024 net loss was SEK -19,157k (H1 2023: SEK -26,018k).

• Cash and cash equivalents at period end were SEK 23,870k, down from SEK 27,950k a year earlier.

• Shareholders' equity at June 30, 2024 was SEK 122,810k, up from SEK 114,958k at June 30, 2023.

Outlook and guidance

• Management expects to finalize the ICOpre® licensing agreement by Q3 2024, with first product launch targeted for 2027.

• The company believes current liquidity is sufficient to finance operations for the next 12 months, even if the ICOpre® out-licensing is delayed.

• Iconovo aims to build a portfolio of inhaled reformulated drugs, focusing on high-growth markets such as GLP-1 for obesity.